Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.56 USD | +0.56% | +2.30% | +562.94% |
05-14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
05-02 | Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 139.7 | 22.12 | 22.78 | 194.5 | - | - |
Enterprise Value (EV) 1 | 139.7 | 22.12 | 22.78 | 194.5 | 194.5 | 194.5 |
P/E ratio | -2.28 x | -0.23 x | -0.4 x | -3.83 x | -3.86 x | -3.43 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -4,360,314 x | - | - | - | - | - |
EV / FCF | -4.63 x | -0.26 x | -0.41 x | -4.55 x | -3.11 x | -2.24 x |
FCF Yield | -21.6% | -387% | -247% | -22% | -32.2% | -44.7% |
Price to Book | 0.99 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 23,198 | 23,285 | 42,415 | 54,638 | - | - |
Reference price 2 | 6.020 | 0.9500 | 0.5370 | 3.560 | 3.560 | 3.560 |
Announcement Date | 22-03-03 | 23-03-09 | 24-03-06 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | -32.03 | - | - | - | - | - |
EBIT 1 | - | -32.05 | -94.55 | -40.34 | -44.57 | -56.11 | -75.18 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -32.04 | -95.06 | -45.67 | -46.51 | -60.12 | -78.18 |
Net income 1 | -17.26 | -32.04 | -95.08 | -45.7 | -48.09 | -60.9 | -78.03 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -21.80 | -2.640 | -4.090 | -1.340 | -0.9283 | -0.9217 | -1.038 |
Free Cash Flow 1 | - | -30.17 | -85.57 | -56.18 | -42.76 | -62.6 | -86.86 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 21-06-04 | 22-03-03 | 23-03-09 | 24-03-06 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | -9.619 | -17.36 | -20.11 | -38.52 | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -9.624 | -17.37 | -20.11 | -38.53 | -18.54 | -16.74 | -9.834 | -10.92 | -7.946 | -9.869 | -10.84 | -11.55 | -12.3 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -9.622 | -17.28 | -19.93 | -38.84 | -19.02 | -17.05 | -10.1 | -10.62 | -7.89 | -10.7 | -11.19 | -11.92 | -12.7 | - | - |
Net income 1 | -9.622 | -17.28 | -19.93 | -38.84 | -19.04 | -17.06 | -10.11 | -10.64 | -7.899 | -10.71 | -11.49 | -12.29 | -13.34 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.4100 | -0.7400 | -0.8600 | -1.670 | -0.8200 | -0.7200 | -0.3700 | -0.2500 | -0.1900 | -0.2300 | -0.2267 | -0.2250 | -0.2400 | -0.2050 | -0.2150 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 22-03-03 | 22-05-05 | 22-08-04 | 22-11-03 | 23-03-09 | 23-05-15 | 23-08-03 | 23-11-02 | 24-03-06 | 24-05-02 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -30.2 | -85.6 | -56.2 | -42.8 | -62.6 | -86.9 |
ROE (net income / shareholders' equity) | - | -29.8% | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | -27.8% | - | - | - | - | - |
Assets 1 | - | 115.2 | - | - | - | - | - |
Book Value Per Share | - | 6.060 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 0.31 | 0.45 | 0.56 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 21-06-04 | 22-03-03 | 23-03-09 | 24-03-06 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+562.94% | 193M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- ELEV Stock
- Financials Elevation Oncology, Inc.